| ADR Ontology |
| ADR Term |
Rhabdomyosarcomas |
| ADR ID |
BADD_A10866 |
| ADR Hierarchy |
|
| Description |
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) [MeSH] |
| MedDRA Code |
10039023 |
| MeSH ID |
D012208
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Rhabdomyosarcoma | Rhabdomyosarcomas |
|
|
| Drugs Leading to the ADR |
| Drug ID | Drug Name | ADR Frequency (FAERS) | ADR Severity Grade (FAERS) | | BADD_D01243 | Lamotrigine | 0.000110% | | | BADD_D01376 | Melphalan | 0.000224% | | | BADD_D01687 | Pazopanib | 0.000224% | |
| The 1th Page 1
Total 1 Pages
|
|
